GGrantIndex
← Search

BIOLOGY OF COLON CANCER PROGRAM

$16,541P30FY2010CANIH

Albert Einstein College Of Medicine, Bronx NY

Investigators

Linked publications, trials & patents

Paper 39499645Paper 39392861Paper 39378878Paper 39332920Paper 39259591Paper 39207105Paper 39193906Paper 39127153Paper 39081315Paper 39028768Paper 39025270Paper 38902475Paper 38898085Paper 38896451Paper 38863869Paper 38778498Paper 38753503Paper 38717519Paper 38700353Paper 38699331Paper 38679747Paper 38657656Paper 38645169Paper 38643166Paper 38608634Paper 38597673Paper 38571760Paper 38565851Paper 38559037Paper 38477945Paper 38463959Paper 38458178Paper 38436133Paper 38405931Paper 38402617Paper 38400039Paper 38387080Paper 38352476Paper 38334805Trial NCT05016622Trial NCT04514484Trial NCT04401670Trial NCT03648983Trial NCT02774291Trial NCT02649569Trial NCT02578888Trial NCT02575872Trial NCT02527304Trial NCT02507076Trial NCT02382419Trial NCT02277561Trial NCT02112552Trial NCT02073968Trial NCT02038153Trial NCT02009436Trial NCT01958580Trial NCT01939210Trial NCT01899326Trial NCT01899261Trial NCT01897454Trial NCT01897441Trial NCT01857271Trial NCT01772420Trial NCT01697293Trial NCT01695941Trial NCT01605032Trial NCT01408160Trial NCT01367301Trial NCT01351909Trial NCT01319539Trial NCT01231906Trial NCT01145430Trial NCT01142401Trial NCT01061606Trial NCT01041027Trial NCT01001910Trial NCT00950365Trial NCT00470301Trial NCT00450944Trial NCT00437034Trial NCT00392353Trial NCT00324740Trial NCT00182767Trial NCT00179348Trial NCT00121251Trial NCT00096317Trial NCT00066638Trial NCT00057863Trial NCT00055692Trial NCT00030706Trial NCT00019474Trial NCT00004864Trial NCT00004863Trial NCT00003867Trial NCT00002461Patent 9671391Patent 7709613Patent 6821725Patent 6013468Patent 5876979

Abstract

The Biology of Colon Cancer is program remains focused on fundamental cellular and molecular mechanisms of intestinal cell maturation and lineage specific differentiation, and how this establishes and maintains homeostasis of the intestinal mucosa;genetic and environmental factors, and their interactions, that perturb these processes and alter probability of tumor formation and progression;and approaches to prevent tumorigenesis and treat intestinal cancer. Members utilize novel cell systems in culture, mouse genetic models, and human tissues and subjects in their investigations. All of the members are independently funded by grants that are highly cancer focused, and most participate in large multidisciplinary programs that are jointly funded. During the last funding period, this included an NCI U01 Director's Challenge grant on molecular markers of relative drug sensitivity in colon cancer, and subsequently an NCI U54 Center grant on nutritional-genetic interactions in intestinal cancer. This joint funding, and a large number of joint publications, reflects the extensive interactions and collaborations among members of the Program. Moreover, members of the Program collaborate widely across the AECC and have made unique resources available to other Center members. The Program has continued to grow during the last 5 years, both by promotion from within and recruitment, made possible by support from the AECC and a pilot project program funded by the U54 Center grant. Leonard Augenlicht remains the Leader of this Program. There are currently 12 program members from 8 departments, of whom 11 are primary members, supported by 15 NCI ($3.7M Direct) and 2 other NIH grants. Five members are new to the program. Since the last CCSG review there have been 105 cancer-relevant research papers by members of this program of which 34% represent intraprogrammatic, and 33% represent interprogrammatic publications.

View original record on NIH RePORTER →